VXRT Key Statistics, Chart & Performance
The current stock price of VXRT is 0.32 USD. In the past month the price decreased by -19.09%. In the past year, price decreased by -52.26%.
VXRT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About VXRT
Company Profile
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The firm's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
Company Info
VAXART INC
170 Harbor Way, Suite 300
South San Francisco CALIFORNIA 94080 US
CEO: Andrei Floroiu
Employees: 105
Phone: 16505503500
VAXART INC / VXRT FAQ
Can you describe the business of VAXART INC?
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The firm's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
What is the current price of VXRT stock?
The current stock price of VXRT is 0.32 USD. The price decreased by -25.06% in the last trading session.
Does VXRT stock pay dividends?
VXRT does not pay a dividend.
What is the ChartMill technical and fundamental rating of VXRT stock?
VXRT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists VXRT stock?
VXRT stock is listed on the Nasdaq exchange.
Should I buy VXRT stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VXRT.
What is VAXART INC worth?
VAXART INC (VXRT) has a market capitalization of 73.03M USD. This makes VXRT a Micro Cap stock.
VXRT Technical Analysis
VXRT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VXRT. Both the profitability and financial health of VXRT have multiple concerns.
VXRT Financial Highlights
Over the last trailing twelve months VXRT reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 49.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.66% | ||
| ROE | -127.41% | ||
| Debt/Equity | 0.01 |
VXRT Forecast & Estimates
9 analysts have analysed VXRT and the average price target is 3.06 USD. This implies a price increase of 856.25% is expected in the next year compared to the current price of 0.32.
For the next year, analysts expect an EPS growth of 15.8% and a revenue growth -37.03% for VXRT